DRUG TREATMENT STUDY
Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21 Day Treatment Study, Including an fMRI sub-study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke
Status: Enrollment closed as of December 2017
Sponsor: Dart NeuroScience, LLC (Commercial)
Site PI: Richard Zorowitz
More Info: Enrolled subjects will have mild to moderately severe, unilateral upper extremity motor impairment, and will begin investigational treatment within 2-52 weeks post-stroke. Subjects will undergo standardized upper extremity rehabilitation with a therapist throughout the study.